Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Calidi Biotherapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CLDI
American
8731
https://www.calidibio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Calidi Biotherapeutics Inc
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
- Apr 23rd, 2024 11:00 am
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
- Apr 19th, 2024 8:05 pm
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
- Apr 16th, 2024 12:31 pm
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024
- Apr 9th, 2024 11:00 am
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results
- Mar 15th, 2024 8:05 pm
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
- Mar 11th, 2024 11:00 am
Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference
- Feb 12th, 2024 12:00 pm
Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board
- Jan 8th, 2024 12:00 pm
Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit
- Dec 13th, 2023 12:00 pm
Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors
- Dec 12th, 2023 12:00 pm
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones
- Nov 20th, 2023 12:00 pm
Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results
- Nov 14th, 2023 9:05 pm
Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)
- Nov 3rd, 2023 11:00 am
Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment
- Nov 1st, 2023 11:00 am
Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer
- Oct 30th, 2023 11:00 am
Calidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023
- Oct 10th, 2023 11:00 am
Scroll